These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17596580)

  • 1. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Warren JL; Brown ML
    J Natl Cancer Inst; 2007 Jul; 99(13):1050; author reply 1051-2. PubMed ID: 17596580
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
    J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
    Touw IP; Bontenbal M
    J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Ferretti G; Papaldo P
    Breast Cancer Res Treat; 2008 May; 109(1):187-8. PubMed ID: 17616805
    [No Abstract]   [Full Text] [Related]  

  • 7. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia and myelodysplastic syndrome following breast cancer: increased frequency of other cancers and of cancers in multiple family members.
    Padmanabhan A; Baker JA; Zirpoli G; Sait SN; Ford LA; Moysich KB; Baer MR
    Leuk Res; 2008 Dec; 32(12):1820-3. PubMed ID: 18468682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome.
    Lyman GH; Kuderer NM
    Cancer Treat Res; 2011; 157():167-78. PubMed ID: 21052956
    [No Abstract]   [Full Text] [Related]  

  • 10. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
    Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
    Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.
    Morton LM; Dores GM; Schonfeld SJ; Linet MS; Sigel BS; Lam CJK; Tucker MA; Curtis RE
    JAMA Oncol; 2019 Mar; 5(3):318-325. PubMed ID: 30570657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute myelogenous leukemia and myelodysplastic syndrome after treatment with cytostatic agents].
    Abrahamsen AF
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2542-5. PubMed ID: 11070993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
    Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
    J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
    Smith RE
    Clin Breast Cancer; 2003 Oct; 4(4):273-9. PubMed ID: 14651772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
    Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
    Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
    Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer.
    Du XL; Zhang Y; Hardy D
    Cancer Causes Control; 2016 May; 27(5):695-707. PubMed ID: 27059219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients.
    Pitini V; Arrigo C; Aloi G; Righi M; Falduto M; Teti D
    Haematologica; 2001 Oct; 86(10):E30. PubMed ID: 11602437
    [No Abstract]   [Full Text] [Related]  

  • 19. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.
    Lipshultz SE; Lipsitz SR; Orav EJ
    J Clin Oncol; 2007 Jul; 25(21):3179; author reply 3180. PubMed ID: 17634500
    [No Abstract]   [Full Text] [Related]  

  • 20. Insulin dependent diabetes mellitus induced by chemotherapy and granulocyte, macrophage--colony stimulating factor.
    Geetha N; Lali VS; Hussain BM; Nair MK
    J Assoc Physicians India; 1999 Aug; 47(8):835. PubMed ID: 10778638
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.